A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Solid Tumours Harboring NRG1 FusionNSCLC Harboring NRG1 FusionPancreatic Cancer Harboring NRG1 FusionNRG1 Fusion
Interventions
DRUG

zenocutuzumab (MCLA-128)

full length IgG1 bispecific antibody targeting HER2 and HER3

Trial Locations (64)

20162

Niguarda Cancer Centre, Milan

28040

START Hospital Fundación Jiménez Diaz, Madrid

28050

START Hospital Universitario Madrid Sanchinarro, Madrid

48201

Karmanos Cancer Center, Detroit

94805

Institut Gustave Roussy, Paris

Unknown

Mayo Clinic, Phoenix

The Oncology Institute of Hope and Innovation, Cerritos

University of California Irvine, Irvine

Stanford University, Palo Alto

Sharp Memorial Hospital, San Diego

Georgetown University, Washington D.C.

Memorial Cancer Institute, Hollywood

Cancer Specialists of North Florida, Jacksonville

Mayo Clinic, Jacksonville

Emory Winship Cancer Institute, Atlanta

Northwest Oncology & Hematology, Rolling Meadows

Dana Farber Cancer Center, Boston

Mayo Clinic, Rochester

Billings Clinic Cancer Center, Billings

St. James Healthcare, Butte

Memorial Sloan Kettering Cancer Center, New York

University of Pennsylvania, Philadelphia

Averra Medical Group, Sioux Falls

The University of Texas MD Anderson Cancer Center, Houston

Huntsman Cancer Institute, Salt Lake City

Utah Cancer Specialists, Salt Lake City

Hematology-Oncology Specialist of Fredericksburg, Fredericksburg

Virginia Mason Hospital & Seattle Medical Center, Seattle

Hematology Oncology Associates, Spokane

Northwest Medical Specialties, Tacoma

Salzburger Universitatsklinikum, Salzburg

UZ Leuven, Leuven

Rigshospitalet, Copenhagen

Centre Leon Berard, Lyon

Hospital Louis Pradel, FR, Lyon

Hopital Cochin, Paris

Hopital Curie, Paris

Asklepios Klinik Altona, Hamburg

Asklepios Kliniken Hamburg GmbH, Hamburg

Deutsches Krebsforschungszentrum, Heidelberg

Shaare Zedek Medical Center, Jerusalem

Sheba Medical Center, Tel Aviv

Ospedale San Raffaele, Milan

Istituti Fisioterapici Ospitalieri, Roma

National Cancer Center Hospital, Chūōku

St. Marianna University School of Medicine Hospital, Kawasaki

Osaka International Cancer Institute, Osaka

National Cancer Center East, Tokyo

Amsterdam Medical Center, Amsterdam

Radboud University Medical Center, Nijmegen

National Cancer Centre of Singapore PTE LTD, Singapore

Samsung Medical Center, Seoul

Seoul National University College of Medicine, Seoul

Severance Hospital- Yonsei Cancer Center, Seoul

Hospital 12 de Octubre, Madrid

Clínica Universidad de Navarra, Pamplona

Instituto Valenciano Oncologia, Valencia

Karolinska Universitetssjukhuset, Solna

National Taiwan University Hospital 7, Taipei

Sarah Cannon Research Institute, London

M5G2M9

Princess MargaretCancer Centre, Toronto

1066 CX

NKI, Amsterdam

0379

University Hospital Oslo, Oslo

08035

Vall D'Hebron Institute of Oncology (VHIO), Barcelona

Sponsors
All Listed Sponsors
lead

Partner Therapeutics, Inc.

INDUSTRY